| Primary |
| Prostate Cancer |
54.7% |
| Product Used For Unknown Indication |
10.5% |
| Chronic Lymphocytic Leukaemia |
4.5% |
| Prostate Cancer Metastatic |
3.9% |
| Hypertension |
3.6% |
| Atrial Fibrillation |
3.3% |
| Drug Use For Unknown Indication |
2.1% |
| Prophylaxis |
2.1% |
| Pain |
1.8% |
| Aortic Valve Replacement |
1.5% |
| Benign Prostatic Hyperplasia |
1.5% |
| Diffuse Large B-cell Lymphoma |
1.5% |
| Prostatic Specific Antigen Increased |
1.5% |
| Arrhythmia |
1.2% |
| Asthma |
1.2% |
| Diabetes Mellitus |
1.2% |
| Pneumonia Bacterial |
1.2% |
| Cardiac Failure Congestive |
0.9% |
| Prostatic Operation |
0.9% |
| Prostatic Specific Antigen |
0.9% |
|
| Subdural Haematoma |
9.0% |
| Drug Ineffective |
7.7% |
| Osteoporosis |
7.7% |
| International Normalised Ratio Increased |
6.4% |
| Orthostatic Hypotension |
6.4% |
| Electrocardiogram Qt Prolonged |
5.1% |
| Neutropenia |
5.1% |
| Prostatic Specific Antigen Increased |
5.1% |
| Somnolence |
5.1% |
| Thrombocytopenia |
5.1% |
| Anaemia |
3.8% |
| Cardiac Failure |
3.8% |
| Pneumonia |
3.8% |
| Prostate Cancer |
3.8% |
| Pruritus |
3.8% |
| Tachycardia |
3.8% |
| Toxic Skin Eruption |
3.8% |
| Vertigo |
3.8% |
| Vomiting |
3.8% |
| Angina Unstable |
2.6% |
|
| Secondary |
| Prostate Cancer |
40.6% |
| Product Used For Unknown Indication |
17.0% |
| Hypertension |
6.9% |
| Prostate Cancer Metastatic |
6.9% |
| Antiandrogen Therapy |
5.5% |
| Drug Use For Unknown Indication |
4.5% |
| Angina Pectoris |
2.6% |
| Diabetes Mellitus |
2.3% |
| Prostate Cancer Stage Ii |
1.9% |
| Rash |
1.6% |
| Prostate Cancer Stage Iii |
1.3% |
| Antibiotic Prophylaxis |
1.2% |
| Depression |
1.1% |
| Gastritis |
1.1% |
| Hypercholesterolaemia |
1.1% |
| Prostate Cancer Stage Iv |
1.1% |
| Prostatic Specific Antigen Increased |
0.9% |
| Benign Prostatic Hyperplasia |
0.8% |
| Blood Cholesterol |
0.8% |
| Parkinson's Disease |
0.8% |
|
| Interstitial Lung Disease |
21.2% |
| Off Label Use |
17.2% |
| Renal Failure Acute |
6.1% |
| Tinnitus |
5.1% |
| Vertigo |
5.1% |
| Cerebral Infarction |
4.0% |
| Coronary Artery Disease |
4.0% |
| Prostate Cancer |
4.0% |
| Skin Infection |
4.0% |
| Thrombosis |
4.0% |
| Drug Hypersensitivity |
3.0% |
| Osteoporosis |
3.0% |
| Pleural Effusion |
3.0% |
| Weight Increased |
3.0% |
| White Blood Cell Count Decreased |
3.0% |
| Acute Febrile Neutrophilic Dermatosis |
2.0% |
| Acute Myocardial Infarction |
2.0% |
| Delirium |
2.0% |
| Depression |
2.0% |
| Diabetes Mellitus |
2.0% |
|
| Concomitant |
| Prostate Cancer Stage Iv |
20.6% |
| Prostate Cancer |
14.7% |
| Product Used For Unknown Indication |
14.0% |
| Drug Use For Unknown Indication |
12.6% |
| Prostate Cancer Stage Ii |
6.5% |
| Hypertension |
5.3% |
| Prostate Cancer Stage Iii |
4.3% |
| Benign Prostatic Hyperplasia |
3.7% |
| Constipation |
2.4% |
| Prostate Cancer Metastatic |
2.0% |
| Diabetes Mellitus |
2.0% |
| Cancer Pain |
1.8% |
| Gastritis |
1.8% |
| Metastases To Bone |
1.5% |
| Prophylaxis |
1.4% |
| Cardiac Failure |
1.3% |
| Gastric Ulcer |
1.2% |
| Pain |
1.1% |
| Insomnia |
1.0% |
| Cerebral Infarction |
0.8% |
|
| Prostate Cancer |
30.1% |
| Prostate Cancer Stage Iv |
10.1% |
| Death |
7.9% |
| Pneumonia |
6.9% |
| Prostatic Specific Antigen Increased |
5.3% |
| Vomiting |
4.2% |
| Pyrexia |
3.8% |
| Cardiac Failure |
3.0% |
| Respiratory Failure |
3.0% |
| Weight Decreased |
3.0% |
| Gastric Cancer |
2.8% |
| Renal Failure |
2.8% |
| Lung Neoplasm Malignant |
2.4% |
| Myocardial Infarction |
2.4% |
| Injection Site Induration |
2.2% |
| Osteonecrosis Of Jaw |
2.2% |
| Urinary Retention |
2.2% |
| Interstitial Lung Disease |
2.0% |
| Metastases To Bone |
2.0% |
| Pancreatitis Acute |
2.0% |
|
| Interacting |
| Hypertension |
18.2% |
| Pneumonia Bacterial |
18.2% |
| Angina Pectoris |
9.1% |
| Arrhythmia |
9.1% |
| Asthma |
9.1% |
| Depression |
9.1% |
| Hyperlipidaemia |
9.1% |
| Hypertrophy |
9.1% |
| Prostate Cancer |
9.1% |
|
| Torsade De Pointes |
100.0% |
|
